1. Antiresorptive dose-response relationships across three generations of bisphosphonates.;Sietsema;Drugs Exp Clin Res,1989
2. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.;Mortensen;J Clin Endocrinol Metab,1998
3. Paget’s disease of bone: reduction of disease activity with oral risedronate.;Hosking;Bone,1998
4. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study.;Siris;J Bone Miner Res,1998
5. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget’s disease.;Singer;J Clin Endocrinol Metab,1998